Literature DB >> 9751643

Substrate specificity of prostate-specific antigen (PSA).

G S Coombs1, R C Bergstrom, J L Pellequer, S I Baker, M Navre, M M Smith, J A Tainer, E L Madison, D R Corey.   

Abstract

BACKGROUND: The serine protease prostate-specific antigen (PSA) is a useful clinical marker for prostatic malignancy. PSA is a member of the kallikrein subgroup of the (chymo)trypsin serine protease family, but differs from the prototypical member of this subgroup, tissue kallikrein, in possessing a specificity more similar to that of chymotrypsin than trypsin. We report the use of two strategies, substrate phage display and iterative optimization of natural cleavage sites, to identify labile sequences for PSA cleavage.
RESULTS: Iterative optimization and substrate phage display converged on the amino-acid sequence SS(Y/F)Y decreases S(G/S) as preferred subsite occupancy for PSA. These sequences were cleaved by PSA with catalytic efficiencies as high as 2200-3100 M-1 s-1, compared with values of 2-46 M-1 s-1 for peptides containing likely physiological target sequences of PSA from the protein semenogelin. Substrate residues that bind to secondary (non-S1) subsites have a critical role in defining labile substrates and can even cause otherwise disfavored amino acids to bind in the primary specificity (S1) pocket.
CONCLUSION: The importance of secondary subsites in defining both the specificity and efficiency of cleavage suggests that substrate recognition by PSA is mediated by an extended binding site. Elucidation of preferred subsite occupancy allowed refinement of the structural model of PSA and should facilitate the development of more sensitive activity-based assays and the design of potent inhibitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751643     DOI: 10.1016/s1074-5521(98)90004-7

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  22 in total

1.  Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Authors:  Meredith R Clark; Hyder A Aliyar; Chang-won Lee; Julie I Jay; Kavita M Gupta; Karen M Watson; Russell J Stewart; Robert W Buckheit; Patrick F Kiser
Journal:  Int J Pharm       Date:  2011-04-12       Impact factor: 5.875

Review 2.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

Review 3.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

4.  Engineering of human coagulation factor x variants activated by prostate-specific antigen.

Authors:  Tina Völkel; Hans-Heinrich Heidtmann; Rolf Müller; Roland E Kontermann
Journal:  Mol Biotechnol       Date:  2005-01       Impact factor: 2.695

5.  Enzyme-triggered gelation: targeting proteases with internal cleavage sites.

Authors:  Steven C Bremmer; Anne J McNeil; Matthew B Soellner
Journal:  Chem Commun (Camb)       Date:  2014-02-18       Impact factor: 6.222

6.  Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.

Authors:  Subha Bakthavatsalam; Petpailin Wiangnak; Daniel J George; Tian Zhang; Katherine J Franz
Journal:  Bioorg Med Chem Lett       Date:  2020-03-28       Impact factor: 2.823

Review 7.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

8.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

9.  Molecular insights into substrate specificity of prostate specific antigen through structural modeling.

Authors:  Pratap Singh; Aaron M LeBeau; Hans Lilja; Samuel R Denmeade; John T Isaacs
Journal:  Proteins       Date:  2009-12

10.  Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins.

Authors:  John P Hobson; Shihui Liu; Stephen H Leppla; Thomas H Bugge
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.